Vomiting clinical trials at UCSF
1 research study open to eligible people
Vomiting is when your stomach forcefully empties its contents through your mouth. UCSF is currently conducting a clinical trial for children undergoing intense cancer treatments who experience vomiting. This trial involves testing a medication called Olanzapine to control Chemotherapy-induced nausea and vomiting (CINV).
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
open to eligible people ages 30 months to 18 years
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
San Francisco, California and other locations
Our lead scientists for Vomiting research studies include Christopher Dvorak.